MRI Assessment of Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease

Joseph A. Helpern, Sang Pil Lee, Maria F. Falangola, Victor V. Dyakin, Adam Bogart, Babak Ardekani, Karen Duff, Craig A. Branch, Thomas Wisniewski, Mony J. De Leon, Oliver Wolf, Jacqueline O'Shea, Ralph A. Nixon

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

The cerebral deposition of amyloid β-peptide, a central event in Alzheimer's disease (AD) pathogenesis, begins several years before the onset of clinical symptoms. Noninvasive detection of AD pathology at this initial stage would facilitate intervention and enhance treatment success. In this study, high-field MRI was used to detect changes in regional brain MR relaxation times in three types of mice: 1) transgenic mice (PS/APP) carrying both mutant genes for amyloid precursor protein (APP) and presenilin (PS), which have high levels and clear accumulation of β-amyloid in several brain regions, starting from 10 weeks of age; 2) transgenic mice (PS) carrying only a mutant gene for presenilin (PS), which show subtly elevated levels of β-peptide without β-amyloid deposition; and 3) nontransgenic (NTg) littermates as controls. The transverse relaxation time T2, an intrinsic MR parameter thought to reflect impaired cell physiology, was significantly reduced in the hippocampus, cingulate, and retrosplenial cortex, but not the corpus callosum, of PS-APP mice compared to NTg. No differences in T1 values or proton density were detected between any groups of mice. These results indicate that T2 may be a sensitive marker of abnormalities in this transgenic mouse model of AD.

Original languageEnglish (US)
Pages (from-to)794-798
Number of pages5
JournalMagnetic Resonance in Medicine
Volume51
Issue number4
DOIs
StatePublished - Apr 2004

Fingerprint

Presenilins
Transgenic Mice
Alzheimer Disease
Amyloid beta-Protein Precursor
Amyloid
Cell Physiological Phenomena
Peptides
Corpus Callosum
Gyrus Cinguli
Brain
Genes
Protons
Hippocampus
Neuropathology
Pathology

Keywords

  • β-amyloid
  • Alzheimer's disease
  • MRI
  • Transgenic mice

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Helpern, J. A., Lee, S. P., Falangola, M. F., Dyakin, V. V., Bogart, A., Ardekani, B., ... Nixon, R. A. (2004). MRI Assessment of Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease. Magnetic Resonance in Medicine, 51(4), 794-798. https://doi.org/10.1002/mrm.20038

MRI Assessment of Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease. / Helpern, Joseph A.; Lee, Sang Pil; Falangola, Maria F.; Dyakin, Victor V.; Bogart, Adam; Ardekani, Babak; Duff, Karen; Branch, Craig A.; Wisniewski, Thomas; De Leon, Mony J.; Wolf, Oliver; O'Shea, Jacqueline; Nixon, Ralph A.

In: Magnetic Resonance in Medicine, Vol. 51, No. 4, 04.2004, p. 794-798.

Research output: Contribution to journalArticle

Helpern, JA, Lee, SP, Falangola, MF, Dyakin, VV, Bogart, A, Ardekani, B, Duff, K, Branch, CA, Wisniewski, T, De Leon, MJ, Wolf, O, O'Shea, J & Nixon, RA 2004, 'MRI Assessment of Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease', Magnetic Resonance in Medicine, vol. 51, no. 4, pp. 794-798. https://doi.org/10.1002/mrm.20038
Helpern JA, Lee SP, Falangola MF, Dyakin VV, Bogart A, Ardekani B et al. MRI Assessment of Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease. Magnetic Resonance in Medicine. 2004 Apr;51(4):794-798. https://doi.org/10.1002/mrm.20038
Helpern, Joseph A. ; Lee, Sang Pil ; Falangola, Maria F. ; Dyakin, Victor V. ; Bogart, Adam ; Ardekani, Babak ; Duff, Karen ; Branch, Craig A. ; Wisniewski, Thomas ; De Leon, Mony J. ; Wolf, Oliver ; O'Shea, Jacqueline ; Nixon, Ralph A. / MRI Assessment of Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease. In: Magnetic Resonance in Medicine. 2004 ; Vol. 51, No. 4. pp. 794-798.
@article{9603a99d74a2417bb6fd06361de2a9d7,
title = "MRI Assessment of Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease",
abstract = "The cerebral deposition of amyloid β-peptide, a central event in Alzheimer's disease (AD) pathogenesis, begins several years before the onset of clinical symptoms. Noninvasive detection of AD pathology at this initial stage would facilitate intervention and enhance treatment success. In this study, high-field MRI was used to detect changes in regional brain MR relaxation times in three types of mice: 1) transgenic mice (PS/APP) carrying both mutant genes for amyloid precursor protein (APP) and presenilin (PS), which have high levels and clear accumulation of β-amyloid in several brain regions, starting from 10 weeks of age; 2) transgenic mice (PS) carrying only a mutant gene for presenilin (PS), which show subtly elevated levels of β-peptide without β-amyloid deposition; and 3) nontransgenic (NTg) littermates as controls. The transverse relaxation time T2, an intrinsic MR parameter thought to reflect impaired cell physiology, was significantly reduced in the hippocampus, cingulate, and retrosplenial cortex, but not the corpus callosum, of PS-APP mice compared to NTg. No differences in T1 values or proton density were detected between any groups of mice. These results indicate that T2 may be a sensitive marker of abnormalities in this transgenic mouse model of AD.",
keywords = "β-amyloid, Alzheimer's disease, MRI, Transgenic mice",
author = "Helpern, {Joseph A.} and Lee, {Sang Pil} and Falangola, {Maria F.} and Dyakin, {Victor V.} and Adam Bogart and Babak Ardekani and Karen Duff and Branch, {Craig A.} and Thomas Wisniewski and {De Leon}, {Mony J.} and Oliver Wolf and Jacqueline O'Shea and Nixon, {Ralph A.}",
year = "2004",
month = "4",
doi = "10.1002/mrm.20038",
language = "English (US)",
volume = "51",
pages = "794--798",
journal = "Magnetic Resonance in Medicine",
issn = "0740-3194",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - MRI Assessment of Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease

AU - Helpern, Joseph A.

AU - Lee, Sang Pil

AU - Falangola, Maria F.

AU - Dyakin, Victor V.

AU - Bogart, Adam

AU - Ardekani, Babak

AU - Duff, Karen

AU - Branch, Craig A.

AU - Wisniewski, Thomas

AU - De Leon, Mony J.

AU - Wolf, Oliver

AU - O'Shea, Jacqueline

AU - Nixon, Ralph A.

PY - 2004/4

Y1 - 2004/4

N2 - The cerebral deposition of amyloid β-peptide, a central event in Alzheimer's disease (AD) pathogenesis, begins several years before the onset of clinical symptoms. Noninvasive detection of AD pathology at this initial stage would facilitate intervention and enhance treatment success. In this study, high-field MRI was used to detect changes in regional brain MR relaxation times in three types of mice: 1) transgenic mice (PS/APP) carrying both mutant genes for amyloid precursor protein (APP) and presenilin (PS), which have high levels and clear accumulation of β-amyloid in several brain regions, starting from 10 weeks of age; 2) transgenic mice (PS) carrying only a mutant gene for presenilin (PS), which show subtly elevated levels of β-peptide without β-amyloid deposition; and 3) nontransgenic (NTg) littermates as controls. The transverse relaxation time T2, an intrinsic MR parameter thought to reflect impaired cell physiology, was significantly reduced in the hippocampus, cingulate, and retrosplenial cortex, but not the corpus callosum, of PS-APP mice compared to NTg. No differences in T1 values or proton density were detected between any groups of mice. These results indicate that T2 may be a sensitive marker of abnormalities in this transgenic mouse model of AD.

AB - The cerebral deposition of amyloid β-peptide, a central event in Alzheimer's disease (AD) pathogenesis, begins several years before the onset of clinical symptoms. Noninvasive detection of AD pathology at this initial stage would facilitate intervention and enhance treatment success. In this study, high-field MRI was used to detect changes in regional brain MR relaxation times in three types of mice: 1) transgenic mice (PS/APP) carrying both mutant genes for amyloid precursor protein (APP) and presenilin (PS), which have high levels and clear accumulation of β-amyloid in several brain regions, starting from 10 weeks of age; 2) transgenic mice (PS) carrying only a mutant gene for presenilin (PS), which show subtly elevated levels of β-peptide without β-amyloid deposition; and 3) nontransgenic (NTg) littermates as controls. The transverse relaxation time T2, an intrinsic MR parameter thought to reflect impaired cell physiology, was significantly reduced in the hippocampus, cingulate, and retrosplenial cortex, but not the corpus callosum, of PS-APP mice compared to NTg. No differences in T1 values or proton density were detected between any groups of mice. These results indicate that T2 may be a sensitive marker of abnormalities in this transgenic mouse model of AD.

KW - β-amyloid

KW - Alzheimer's disease

KW - MRI

KW - Transgenic mice

UR - http://www.scopus.com/inward/record.url?scp=12144291398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144291398&partnerID=8YFLogxK

U2 - 10.1002/mrm.20038

DO - 10.1002/mrm.20038

M3 - Article

VL - 51

SP - 794

EP - 798

JO - Magnetic Resonance in Medicine

JF - Magnetic Resonance in Medicine

SN - 0740-3194

IS - 4

ER -